Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-25 09:42:44 阅读(143)
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
上一篇:Will Nifty reclaim 20200 or fall in trade- 8 things to know before share market opens
下一篇:Year-ahead -Top realtors expect 10-15% jump in home sales
猜你喜欢
- SGX Nifty sits in red, 17800 to act as resistance for Nifty; 5 things to know before today’s opening bell
- Your Money- Don’t let your health plan lapse
- Set-up for USDINR remains bearish, fears of further rate hikes spook traders; Fed Chair Powell’s speech eyed
- Windfall taxes cut on diesel, scrapped on ATF; Crude cess up a tad
- SGX Nifty up, global cues positive, Nifty outlook, HDFC-HDFC Bank merger; 5 things to watch out for on 5 July
- TATA Technologies files addendum to DRHP
- Share Market Highlights- Nifty settles below 18300, Sensex down 30 pts; Bank Nifty above 43450, Adani Ent surges 5%
- ts. Thus we believe that this company is suitable only for investors having a high-risk appetite and a long-term view.”
(The stock recommendations in this story are by the respective research analysts and brokerage firms. FinancialExpress.com does not bear any responsibility for their investment advice. Capital markets investments are subject to rules and regulations. Please consult your investment advisor before investing.)
- Xiaomi 13 Ultra first look, impressions- Everything to know in 10 points